RNXT RenovoRx, Inc.
$1.31▲ +1.55%
Healthcare
Other
Pre-market
$1.30▼ -0.76%
Oct 27, 4:14 AM ET
Volume 181.7K
Avg Volume (10D) 382.0K
Key Metrics & Fundamentals
Market Cap
$59.12M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.70 - 2.59
% vs 50 MA
-15.33%
% vs 200 MA
19.53%
RSI-14
45.9
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.42
Free Cash Flow
-$2.94M
Gross Rev
$909,000
Gross Profit
$766,000
EBITDA
-$3.69M
COGS
$143,000
Operating Exp
$4.12M
Operating Income
-$3.35M
EBIT
-$3.35M
Pretax Income
-$2.91M
Net Income
-$2.91M
EPS (Diluted)
-0.06
Price & Volume History
Loading chart…
Recent News
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
GlobeNewswire · Oct 22, 2026 8:45 AM ET
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
GlobeNewswire · Oct 7, 2026 8:30 AM ET
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
GlobeNewswire · Oct 1, 2026 8:30 AM ET
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
InvestorsHub · Sep 2, 2026 10:39 AM ET
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
GlobeNewswire · Sep 2, 2026 8:30 AM ET
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
GlobeNewswire · Aug 25, 2026 8:30 AM ET
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire · Aug 21, 2026 8:30 AM ET
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
GlobeNewswire · Aug 20, 2026 8:30 AM ET
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
MarketBeat · Aug 16, 2026 9:01 PM ET
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
GuruFocus.com · Aug 13, 2026 1:02 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RNXT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.